CRA-026440 is a novel, broad-spectrum, hydroxamic acid -based inhibitor of histone deacetylase (HDAC) that shows antitumor and antiangiogenic activities in vitro and in vivo preclinically. CRA-026440 inhibited pure recombinant isozymes HDAC1, HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 in the nanomolar range.
Introduction
Chromatin is structurally complex, consisting of DNA, histone, and nonhistone proteins. Remodeling of the chromatin histone and nonhistone proteins around which the DNA is wrapped is a fundamental epigenetic mechanism regulating gene expression in vertebrates (1) . It has been hypothesized that histone modification, achieved through histone acetyltransferase and histone deacetyltransferase (HDAC) enzymes, plays a key role in the regulation of gene transcription (2 -4) . The removal of acetyl groups from histones changes the accessibility of DNA to transcriptional factors, thus leading to transcriptional repression (2 -4) . In addition to histones, HDAC enzymes are known to deacetylate other proteins, including a-tubulin, suggesting complex, multifunctional roles for HDACs (5) . In addition, HDACs have been reported to mediate the function of oncogenic translocation products in certain leukemias and lymphomas (6 -10) .
HDAC enzymes are divided into three major groups based on sequence, conformation, and function. Class I HDAC1, HDAC2, HDAC3, and HDAC8 are widely expressed in tissue and are largely restricted to the nucleus (11, 12) . HDAC1 and HDAC2 form part of the transcription repression complex SIN3-HDAC and the nucleosome remodeling deacetylase complex NuRD-Mi2-NRD (13) . Class II HDAC4, HDAC5, HDAC6, HDAC7, HDAC9a, HDAC9b, and HDAC10 are much larger in size, display limited tissue distribution, and can shuttle between the nucleus and the cytoplasm (11, 12) . Class III HDACs consist of the sirtuins, proteins that have a unique enzymatic mechanism that is dependent on NAD + (11, 12, 14, 15) . It is hypothesized that histone acetylation may play a role in tumor development and progression (6, 9, 16, 17) . HDAC inhibitors have displayed selective growth inhibition against transformed cells (18 -21) . Treatment of tumor cells with HDAC inhibitors induces growth arrest, differentiation, and the activation of caspase-dependent apoptosis (6, 11, 12) . Moreover, HDAC inhibitors have exhibited inhibition of proliferation, invasion, migration, adhesion, and tube formation of endothelial cells (22) . The expression of angiogenic factors, such as vascular endothelial growth factor (VEGF), and antiangiogenic factors, such as von Hippel Lindau and neurofibromin 2, is also modulated by HDAC inhibitors (11) .
Expression profiling studies have shown that treatment of HDAC inhibitors alters the expression of f2% to 10% of cellular genes (23 -25) . Genes up-regulated by HDAC inhibitors include the tumor suppressor p21
Cip1/WAF1 , p16, gelsolin, histones, TBP-2, and caspases, and down-regulated genes include Her2/neu, VEGF, thioredoxin (26) , and cyclin proteins (27) . Other substrates of HDACs include p53 and BCL6 (6, 10) .
A variety of structurally diverse compounds have been described to inhibit HDAC enzymes, including hydroxamic acids, benzamides, eletrophilic ketones, and cyclic peptides (11, 28 -30) . Several hydroxamic acid -based inhibitors have been described (suberoylanilide hydroxamic acid, trichostatin A, oxamflatin, LAQ824, LBH589, PXD101, and CRA-024781), some of which are currently in clinical trials for cancer. We have focused on the characterization of a hydroxamic acid -based series of compounds optimized for in vivo efficacy and therapeutic index (31, 32) . Herein, we describe the in vitro and in vivo characteristics of a novel HDAC inhibitor, CRA-026440.
Materials and Methods

Cell Lines
The human tumor cell lines were obtained from the American Type Culture Collection (Manassas, VA). They included human colorectal carcinomas (HCT116, HCT-15, and DLD-1), human breast carcinomas (BT-549 and MCF-7), human prostate carcinomas (CWR-22RV1 and NCI-PC3), human ovarian carcinomas (SKOV-3 and OVCAR-3), human lung carcinomas (NCI-H226 and A549), human pancreatic carcinoma (BxPC3), and human histiocytic carcinoma (U937). Human umbilical vein endothelial cells (HUVEC) were obtained from Cambrex (East Rutherford, NJ).
Histone Deacetylase Activity HDAC activity was measured using a continuous trypsin-coupled assay that has been described in detail previously (33) . For each isozyme, the HDAC protein in reaction buffer [50 mmol/L HEPES, 100 mmol/L KCl, 0.001% Tween 20, 5% DMSO (pH 7.4), supplemented with bovine serum albumin at concentrations of 0% (HDAC1), 0.01% (HDAC2, HDAC3, HDAC8, and HDAC10), or 0.05% (HDAC6)] was mixed with inhibitor at various concentrations and allowed to incubate for 15 minutes. Trypsin was added to a final concentration of 50 nmol/L, and acetyl-Gly-Ala-(N-acetyl-Lys)-AMC was added to a final concentration of 25 Amol/L (HDAC1, HDAC3, and HDAC6), 50 Amol/L (HDAC2 and HDAC10), or 100 Amol/L (HDAC8) to initiate the reaction. Negative control reactions were done in the absence of inhibitor in replicates of eight. After a 30-minute lag time, the fluorescence was measured over a 30-minute time frame using an excitation wavelength of 355 nm and a detection wavelength of 460 nm. The increase in fluorescence with time was used as the measure of the reaction rate. Inhibition constants K i(app) were obtained using the program BatchKi (34) .
Cell Proliferation Assay Ten tumor cell lines and HUVECs were cultured for at least two doubling times, and growth was monitored at the end of compound exposure using an Alamar Blue (Biosource, Camarillo, CA) fluorometric cell proliferation assay as described (35). CRA-026440 was assayed in triplicate wells at nine concentrations in half-log intervals from 0.0015 to 10 Amol/L. The concentration required to inhibit cell growth by 50% (GI 50 ) and 95% confidence intervals were estimated from nonlinear regression using a four-variable logistic equation.
Histone and Tubulin Acetylation, p21
Cip1/WAF1 Accumulation, Poly(ADP-Ribose) Polymerase Cleavage, and ;-H2AX
Tumor cells and subconfluent HUVECs were cultured for 18 hours in the presence of CRA-026440 concentrations ranging from 0.1 to 10 Amol/L. Cells were then collected and lysed in lysis buffer (M-Per; Pierce, Rockford, IL) containing protease inhibitors (Complete, Mini, EDTA-free; Roche, Indianapolis, IN) and phosphatase inhibitors (phosphatase inhibitor cocktail set II; Calbiochem, San Diego, CA). Lysates were electrophoresed in Novex Tris-glycine gels (Invitrogen, Carlsbad, CA), which were then blotted onto nitrocellulose and probed with either an anti-acetyl lysine antibody (Upstate, Lake Placid, NY) to detect acetylated histones, an antiacetylated tubulin antibody (Sigma, St. Louis, MO), an anti-p21
Cip1/WAF1 antibody (BD Biosciences, San Jose, CA), an anti-poly(ADP-ribose) polymerase antibody (Cell Signaling, Danvers, MA), or an anti-g-H2AX antibody (Cell Signaling).
Ex vivo Angiogenesis Analysis Aortic arch was isolated surgically from euthanized Fisher rats from Charles Rivers Laboratories (Wilmington, MA). It was sliced into 2-mm slices under aseptic conditions and placed in 48-well plates precoated with 150 AL of Matrigel (BD Biosciences). Aortic sproutings were observed about 3 days after incubation. The culture was then treated with CRA-026440 for an additional 5 days and was stained in crystal violet (0.5% crystal violet, 5% formaldehyde in 50% ethanol, and 50% PBS). The extent of angiogenesis was scored blindly on 0 to 3 scale (0, no sprouting; 1, some sprouting; 2, significant sprouting; and 3, extensive sprouting).
Pharmacokinetic Analysis CRA-026440 was formulated in 20% SBE-h-cyclodextrin (CyDex, Lenexa, KS) in water and was given in i.v. bolus to female HCT 116 tumor-bearing BALB/c nu/nu mice. Plasma was prepared from each blood sample with lithium heparin. Tumor samples were collected and homogenized with 9 volumes of water, and the homogenate was collected. The plasma and tumor homogenate samples were processed using acetonitrile precipitation. The concentrations of CRA-026440 in the supernatants were determined by liquid chromatography tandem mass spectrometry. The limit of quantification was 1 nmol/L. Pharmacokinetic variables were determined with noncompartmental analysis using WinNonlin-Pro version 4.1 (Pharsight Corp., Mountain View, CA). Pharmacokinetic calculations were done using nominal doses and nominal collection times.
In vivo Efficacy Studies Female BALB/c nu/nu mice were purchased from Charles River Laboratories. HCT116 at 3 Â 10 6 and U937 at 4 Â 10 6 were implanted s.c. Tumor-bearing mice were randomized based on tumor volume before the initiation of treatment. The treatment duration was 2 and 3 weeks for the U937 and the HCT 116 xenograft models, respectively. For combination studies, Avastin (Genentech, South San Francisco, CA) was given i.p. once a week, a day before the i.v. administration of CRA-026440. Tumor volume was calculated as follows: volume = 1/2 (X 2 Y), where X = tumor width and Y = tumor length. Inhibition of tumor growth was calculated as follows: 100 Â [1 À (dT/dC)], where dT was the change in average tumor volume since the first dose in the treatment group, and dC was the change in average tumor volume since the first dose in the control group. Statistical analysis was done with one-way ANOVA, and P values were corrected for multiple comparisons to control by Dunnett's method.
Immunohistochemical Analysis HCT 116 tumor-bearing nude mice were treated with CRA-026440 at 100 mg/kg daily for three consecutive days. Tumor xenograft samples were fixed overnight in 10% zinc-buffered formalin and embedded in paraffin. Immunohistochemical staining on Ki67 was done at BioPathology Sciences Medical Corp. (South San Francisco, CA).
Detection of Acetylated Tubulin in Whole Blood
Tumor xenograft and blood samples collected at various time points after dosing. Blood samples were processed in Red Cell Lysis Buffer (Roche) to isolate nucleated blood cells per manufacturer's instruction. Cells were pelleted and stored at À80jC until analysis. Acetylated tubulin was detected in blood lysates by Western blotting.
Microarray Analysis Transcriptional profiles of HCT-116 cell line and tumor xenograft samples were obtained on Codelink Human Uniset 1 oligonucleotide microarrays (GE-Amersham, Piscataway, NJ) as described previously (31) . For the cell line samples, total RNA was isolated from cells incubated with 0.31 Amol/L CRA-26440 for 2, 4, or 24 hours. For tumor samples, HCT-116 tumor-bearing mice received three consecutive daily i.v. doses of CRA-26440 or vehicle. Equal amounts of RNA from at least three animals per dose per time point were pooled together for analysis. Ten micrograms of biotinylated cRNA were fragmented and hybridized to the arrays. Arrays were hybridized, washed, and detected with Strepatavidin-Alexa 647 (Codelink Protocol v2.1). They were scanned with an Axon GenePix 4000B scanner (Axon Instruments, Sunnyvale, CA) and were processed with Codelink 4.0 Batch Processing software. The data were analyzed in Genespring (Agilent, Inc., Palo Alto, CA). Only genes flagged as Good by the Codelink quality control software were used in the analyses. Each treated sample was normalized to the corresponding vehicle control.
Taqman Analysis Taqman Gene Expression Assays for selected genes were obtained from Applied Biosystems, Inc. (Foster City, CA). One-step reverse transcription-PCR was carried out in triplicate on 25 ng of total RNA from each sample on an ABI PRISM 7700 instrument according to standard protocols. The mRNA levels for each gene were normalized to the amount of RNA in the well as measured in parallel using Ribogreen (Molecular Probes, Carlsbad, CA). The treated samples were then normalized to the vehicle control for that time point. 
Results
Chemical Design and Synthesis
In the design of inhibitors of histone deacetylase, phenyl hydroxamic acids were employed as chelators of the active site Zinc(II). Further elaboration led to the aminopropynyl linking group attachment to the para-position of the phenyl hydroxamic acid. The aminopropynyl linking group was further modified by the addition of the 5-(2-dimethylaminoethoxy) indole capping group, which resulted in the potent, broad-spectrum histone deacetylase inhibitor CRA-026440 (Fig. 1) .
Effect onTumor Cell Proliferation
To determine if HDAC inhibition by CRA-026440 affects the proliferation of tumor cells, a panel of human tumor cell lines was treated in vitro at various concentrations of inhibitor. Antitumor activity was observed in all 10 tumor cell lines tested, with GI 50 values ranging from 0.12 to 9.95 Amol/L (Table 1 ). In addition, CRA-026440 had antiproliferative effect on HUVEC endothelial cells with a GI 50 value of 1.41 Amol/L (Table 1; Fig. 2) .
Effect on Protein Acetylation, p21 Cip1/WAF1 Induction, and the Apoptosis Markers Poly(ADP-Ribose) Polymerase and ;-H2AX
We further characterized the antitumor mechanism of CRA-026440 by treating HCT116 colorectal tumor cells with increasing concentrations of CRA-026440 in vitro and measuring the accumulation of various mechanistic biomarkers proposed to be involved in the activity of HDAC inhibitors. Treating HCT116 cells with CRA-026440 resulted in the accumulation of both acetylated histones and acetylated tubulin (Fig. 3A) . Acetylated tubulin was detectable at lower concentrations than acetylated histones, which might reflect differing sensitivities for specific HDACs or HDAC substrates, or differing sensitivities of the specific detection reagents used. In addition, CRA-026440 induced expression of the cyclin-dependent kinase inhibitor p21
Cip1/WAF1 , a protein postulated to play a role in the antitumor effect of HDAC inhibition (27, 36) . This was confirmed by the expression profiling study in which p21 mRNA was induced by >2.5-fold in HCT 116 cells after treatment with CRA-026440 for 24 hours (data not shown). In addition, g-H2AX formation, an early chromatin modification event following the initiation of DNA fragmentation during apoptosis (37) was detected along with poly(ADPribose) polymerase cleavage in HCT 116 in the low micromolar range. Although CRA-026440 was less potent in inhibiting HUVEC proliferation, pharmacodynamic analysis revealed similar extent of accumulation of acetylated tubulin in HUVEC upon CRA-026440 treatment (Fig. 3B) .
In vivo Pharmacokinetics
We assessed the pharmacokinetics of the compound to evaluate in vivo exposure. CRA-026440 was delivered i.v. to mice, and plasma concentrations were monitored over time (Fig. 4A ). Based on these data, the clearance was calculated to be 38 mL/min/kg; the volume of distribution in the central compartment was 67 mL/kg. The steady-state volume of distribution was 454 mL/kg. The predominant plasma half-life was 7 minutes (44% of area under the curve); and the mean residence time was 12 minutes. One notable finding is that CRA-026440 had a different pharmacokinetic profile in tumor (Fig. 4B ). It had a lower C max , but the compound concentration was maintained more steadily over time, probably due to the compound's large volume of distribution. These data suggested that CRA-026440 had sufficient in vivo exposure when dosed by the i.v. route of administration to be used to study the biological effects of HDAC inhibition in vivo.
Antitumor Activity and Induction of Acetylation by CRA-026440 In vivo Nude mice bearing human tumor xenografts were dosed i.v. with CRA-026440 once daily for 3 days followed by 4 days without treatment (qdx3). In the U937 histiocytic lymphoma model, statistically significant tumor growth inhibition of 58% (P < 0.05) was achieved after 2 weeks of treatment at 100 mg/kg (Fig. 5A) . A trend toward efficacy, although statistically not significant, was noted at 50 and 25 mg/kg (Fig. 5A ). Treatment at all dose levels was well tolerated with no mortality and 1.6% maximal body weight loss. In the HCT 116 colorectal tumor model, statistically significant tumor growth inhibition was observed after 3 weeks of treatment at 50, 75, 100, and 150 mg/kg (Fig. 5B) . The inhibition of tumor growth was 42% (P < 0.05), 63% (P < 0.01), 77% (P < 0.01), and 93% (P < 0.01), respectively. The treatment was well tolerated at up to 100 mg/kg with a maximal weight loss of 6%. At 150 mg/kg, 9% weight loss and 30% mortality (3 of 10) were noted. The dose of 200 mg/ kg qdx3 was not tolerated. Thus, the maximal tolerated dose under this schedule was f150 mg/kg (qdx3/wk for 3 weeks), as suggested by the mortality and weight loss. Additionally, a separate dose-scheduling study suggested that statistically significant tumor growth inhibition could be achieved at 100 mg/kg once daily for two consecutive days each week, or once daily on Monday and Friday each week (Fig. 5C ). The tumor growth inhibition was 47% (P < 0.01) and 42% (P < 0.01), respectively. Because HDAC inhibition is known to affect the expression of genes involved in angiogenesis, we asked whether CRA-026440 would have greater efficacy in combination with an angiogenic inhibitor. To this end, CRA-026440 was tested in combination with Avastin in the HCT 116 tumor model. In this study, Avastin that was given at 25 mg/kg i.p. once a week yielded a tumor growth inhibition of 63% (P < 0.01). CRA-026440 at 25 and 50 mg/kg given qdx3 per week significantly inhibited tumor growth at 40% (P < 0.01) and 58% (P < 0.01), respectively. The combination of Avastin at 25 mg/kg once a week and CRA-026440 at 25 and 50 mg/kg for three consecutive days per week lead to more profound tumor growth inhibition of 84% (P < 0.01) and 85% (P < 0.01), respectively (Fig. 5D) . Compared with Avastin alone, the combination yielded a marginally better result (P < 0.1). The combination of Avastin and CRA-026440 at 50 mg/kg was significantly better than CRA-026440 alone at 50 mg/kg (P < 0.05). Both combination treatments were well tolerated with maximal weight loss <3%.
Histochemical analysis of HCT 116 tumor xenograft treated with CRA-026440 indicated a reduction of the (Fig. 5E and F) .
To analyze in vivo biomarkers that correlated with compound exposure and/or efficacy, peripheral blood cells and tumor xenograft samples were examined ex vivo. As shown in Fig. 6A , the peripheral blood samples in each treatment group had a measurable increase in tubulin acetylation at 2 and 6 hours after treatment. The level of tubulin acetylation returned to baseline after 24 hours, in agreement with the pharmacokinetic profile of CRA-026440 in circulation. Increased tubulin acetylation in the HCT 116 tumor xenograft was detectable at 24 hours after treatment (Fig. 6B) , indicative of a more prolonged presence of CRA-026440 in tumor than in circulation, in agreement with the tumor pharmacokinetic profile (Fig. 4B) .
Transcriptional Profile of CRA-026440
The transcriptional profile of CRA-26440 in HCT-116 cells and tumors is shown in Fig. 7 , where 100 mg/kg dose in vivo was compared with 0.31 Amol/L dose (the GI 50 for CRA-026440 against HCT 116) in vitro. Genes in each sample were subjected to two-way hierarchical clustering using standard correlation on both the genes (along the vertical axis) and the samples (along the horizontal axis).
There was a notable trend in the expression patterns with time that was conserved in both the in vivo and in vitro samples. In both cases, the initial response was composed of a rapid increase in expression of a set of genes (enclosed by the red box) within 2 hours followed by a more gradual but strong down-regulation of other genes at the mid and late time points (green boxes). The overall number of statistically significant, differentially expressed genes increased with time for both in vitro and in vivo experiments. The genes that were regulated in common between these conditions at each of the early (2 hours), mid (4 -6 hours), or late (24 hours) time points include several that are known to be modulated by HDAC inhibition (31, 38, 39) . The notable examples are the up-regulation of CTGF, DHRS2, FYN, RGL, SERPIN1, and PDE2A and the downregulation of urokinase, NFkB p105, c-MYC, cyclin A1, and the tumor marker CA-9.
Antiangiogenic Activity by CRA-026440
We observed that the expression levels of VEGF was only affected in vivo and not in vitro. In addition, it was also observed that the expression of several other angiogenic genes might have been down-regulated, especially at 24 hours. These included HIF-1a, EGFR, erbB2, angiopoietin-1, KDR (VEGFR2), FGFR3, and FGFR4 (Table 2) . To examine whether CRA-026440 treatment affects the process of angiogenesis, CRA-026440 was tested in the rat aortic ring angiogenesis assay. The rat aortic ring culture was treated with CRA-026440 at 0.1 to 10 Amol/L after the vessels started to sprout. Inhibition by CRA-026440 on sprouting was detectable after 2 days of treatment. After 5 days of treatment, a dose-dependent inhibitory activity was noted in this assay with CRA-026440 at 10 and 1 Amol/L (Fig. 8A -F) .
In summary, CRA-026440 exhibited statistically significant antitumor activity against both HCT116 and U937 human tumor xenografts. Evidence suggesting possible antiangiogenic activity of CRA-026440 was obtained. CRA-026440, when given in combination with Avastin, exhibited additional antitumor activity in the HCT116 xenograft model.
Discussion
A number of HDAC inhibitors have been characterized both in vitro and in vivo (1, 11, 31) , and some are being developed clinically to treat cancer (1, 11, 31, 40) . Different HDAC inhibitors have displayed different selectivity against HDAC isoenzymes; for example, FK228 inhibits HDAC1 and HDAC2 but not HDAC4 or HDAC6 (41) , and MS-275 is potent against HDAC1 and HDAC3 but not HDAC8 (42) . Herein, we have described CRA-026440, a novel hydroxamic acid -based, broadspectrum inhibitor of HDAC enzymes with potent antitumor activity in vitro and in vivo. CRA-026440 inhibited potently all of the HDACs tested with K i values ranging from 4.1 to 20 nmol/L.
CRA-026440 inhibited the growth of a number of human tumor cell lines and nonneoplastic HUVEC in vitro. Growth inhibition was accompanied by changes in several known biomarkers of HDAC response. These biomarkers included the accumulation of acetylated histones and acetylated tubulin, the accumulation of the tumor suppressor protein p21
Cip1/WAF1 , and the generation of cleaved poly(ADP-ribose) polymerase fragment and phosphorylated H2AX, two known markers of apoptosis. CRA-026440 had an in vivo pharmacokinetic profile that suggested adequate exposure to enable HDAC inhibition. One noteworthy finding is that the plasma pharmacokinetic profile of CRA-026440 be different from the tumor pharmacokinetic profile. CRA-026440 was present for much longer duration at HCT 116 tumor xenograft than in circulation. The results suggest of the need to monitor drug exposure at tumors to have a more relevant correlation between exposure and effects. The 50 mg/kg i.v. dose achieved significant tumor growth inhibition in the HCT 116 tumor xenograft model. The in situ concentration of CRA-026440 was maintained above the measured cellular GI 50 for HCT116 tumor cells for f6 hours. The data suggest that in situ CRA-026440 concentration need to be maintained above a threshold for around 6 hours to achieve antitumor efficacy. This is consistent with our observation with another HDAC inhibitor CRA-024781 (31) . Additionally, the preclinical efficacy of CRA-026440 was manifested primarily as tumor growth inhibition and not sustained tumor regression. Thus, it is inferred that CRA-026440 may need to be given on regular basis to achieve sustained antitumor effect.
The expression profiling analysis of HCT 116 treated by CRA-026440 has suggested a possible role of CRA-026440 in angiogenesis. This is supported by the finding in the chronic rat aortic ring assay in which CRA-026440 did exhibit clear, dose-dependent inhibition on vessel sprouting. However, the effect of CRA-026440 on overnight HUVEC tubule formation assay was marginal (data not shown). It must be noted that the potency of CRA-026440 against rat HDAC enzymes is unknown. Thus, it is difficult to directly compare the outcomes of the HUVEC Matrigel and rat aortic ring assays. However, the results may suggest that CRA-026440 would have a more chronic antiangiogenic activity, as was manifested in the aortic ring assay (4 -5 days) rather than an acute activity as was in the Matrigel assay (overnight). Some HDAC inhibitors have been shown to work synergistically or additively with an array of anticancer agents (6, 10, 11) . Here, the notion that HDAC inhibition could potentiate antiangiogenic activity prompted us to examine the combination of Avastin and CRA-026440 in the HCT 116 tumor model. We observed additional efficacy with this combination. Such additive benefit could be achieved at doses of CRA-026440 much below its maximal tolerable dose, without manifesting any noticeable signs of toxicity. This finding suggests that CRA-026440 may be used in combination with a standard angiogenic inhibitor for cancer therapy.
In summary, we have identified a novel inhibitor of HDAC (CRA-026440) with antitumor activity in vitro and in vivo. The results presented here show that CRA-026440 inhibits HDAC enzymes and has antitumor properties NOTE: Selected genes involved in angiogenic processes, which are regulated by HDAC inhibition with CRA-026440 in vivo and in vitro . Genes that are downregulated <1.5-fold are in boldface. Ratios marked with an asterisk could not be calculated due to lack of expression control. CRA-026440 at 100 nmol/L, (G) composite angiogenesis scores of two independent rat aortic ring assays.
